<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718286</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC.STEMI.2018</org_study_id>
    <nct_id>NCT03718286</nct_id>
  </id_info>
  <brief_title>Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI</brief_title>
  <acronym>EPIC STEMI</acronym>
  <official_title>Effects of Acute, Rapid Lowering of Low Density Lipoprotein Cholesterol With Alirocumab in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo controlled parallel group clinical trial evaluating the&#xD;
      effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density&#xD;
      lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary&#xD;
      PCI.&#xD;
&#xD;
      The objective is to determine the effect of acute, rapid lowering of LDL cholesterol with&#xD;
      alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI.&#xD;
      The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL&#xD;
      cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will&#xD;
      favourably affect LDL cholesterol concentrations compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, sham-controlled parallel group clinical trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in direct LDL cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo B</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Dyslipidemias</condition>
  <condition>Physiological Effects of Drugs</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab</intervention_name>
    <description>150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.</description>
    <arm_group_label>Alirocumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Control</intervention_name>
    <description>Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with STEMI defined as both of the following: a) Symptoms of&#xD;
             myocardial ischemia lasting for ≥ 30 minutes, and b) Definite ECG changes indicating&#xD;
             STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in&#xD;
             two contiguous precordial leads.&#xD;
&#xD;
          -  Referred for primary PCI for presenting symptoms.&#xD;
&#xD;
          -  Randomized within 12 hours of symptom onset and prior to diagnostic angiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age ≤18 years.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Current or planned treatment with a PCSK9 inhibitor.&#xD;
&#xD;
          -  Allergy or contra-indication to a PCSK9 inhibitor.&#xD;
&#xD;
          -  Killip class ≥2.&#xD;
&#xD;
          -  Known Creatinine clearance &lt;30mL/min.&#xD;
&#xD;
          -  Suspected takotsubo / stress-induced cardiomyopathy or acute pericarditis.&#xD;
&#xD;
          -  Any other medical, geographic, or social factor making study participation impractical&#xD;
             or precluding follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamir Mehta, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute; McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences, General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

